Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 11;14(1):16005.
doi: 10.1038/s41598-024-66307-3.

Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany

Therese Tzschoppe  1 , Julia Ohlinger  1 , Dirk Vordermark  1 , Ahmed Bedir  1 , Daniel Medenwald  2
Affiliations

Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany

Therese Tzschoppe et al. Sci Rep. .

Abstract

Lung cancer is known for its high mortality; many patients already present with metastases at the time of diagnosis. The aim of this study is to assess the impact of new treatment strategies on the survival of primarily metastatic lung cancer patients and to analyze the differences in outcomes between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients. Population-based data, provided by the Robert-Koch Institute in Germany, was used and patients diagnosed between 2007 and 2018 were included in the study. We differentiated between NSCLC and SCLC patients and analyzed the survival over time for both sexes separately, using the Kaplan-Meier method. To evaluate survival advantages, we calculated multivariable hazard ratios. In total, 127,723 patients were considered for the study. We observed a moderate increase in survival over time. All patients showed an increased survival rate when undergoing chemotherapy. Minimal to no increase in survival was shown in NSCLC patients when receiving radiotherapy, whereas SCLC patients' survival time did benefit from it. NSCLC patients receiving immunotherapy showed an increase in survival as well. It can be concluded that advancements in radiotherapy, the application of chemotherapy, and the introduction of immunotherapies lead to an increased survival time of both NSCLC and SCLC primarily metastatic lung cancer patients.

Keywords: Cancer registry; Germany; Lung cancer; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Robert Koch-Institut (publ.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (publ). Krebs in Deutschland für 2017/2018. 10.25646/8353 (2021).
    1. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, Goldstraw P. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2007;2(8):694–705. doi: 10.1097/JTO.0b013e31812d05d5. - DOI - PubMed
    1. Woodard GA, Jones KD, Jablons DM. Lung Cancer staging and prognosis. Cancer Treatm. Res. 2016;170:47–75. doi: 10.1007/978-3-319-40389-2_3. - DOI - PubMed
    1. Catelan D, Biggeri A, Bucchi L, Manno V, Pappagallo M, Stoppa G, Grippo F, Frova L, Zamagni F, Crialesi R, Minelli G. Epidemiologic transition of lung cancer mortality in Italy by sex, province of residence and birth cohort (1920–1929 to 1960–1969) Int. J. Cancer. 2023;153(10):1746–1757. doi: 10.1002/ijc.34657. - DOI - PubMed

MeSH terms

LinkOut - more resources